About Seth Wander, MD, PhD

Dr. Seth Wander is a medical oncologist at the Massachusetts General Hospital with a clinical and translational research interest in breast cancer and cancer genomics. Dr. Wander completed his undergraduate degree at Cornell University, where he studied Molecular and Cell Biology and graduated magna cum laude with distinction in research. He pursued his MD and PhD in Cancer Biology at the University of Miami. Dr. Wander completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center. 

Dr. Wander is active in both the clinic and laboratory, where his research interests involve genomic mechanisms of resistance to targeted therapies in metastatic breast cancer. He is an instructor in medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award. 

Departments, Centers, & Programs:

Clinical Interests:



Mass General Hospital Cancer Center
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-4000
Phone: 617-726-6500

Spaulding Rehabilitation-Cambridge
1575 Cambridge Street
Cambridge, MA 02138-4308
Phone: 617-349-5708

Medical Education

  • MD, University of Miami
  • M.D.; Ph.D., University of Miami School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Brigham and Women's Hospital
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, Dana-Farber Cancer Institute

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    Selected Publications: 

    Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021 PMID: 34392831.

    Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 PMID: 33761455.

    Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020 PMID: 32404308.

    Wander SA, Mayer EL, Burstein HJ. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 PMID: 28580881.

    Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011 PMID: 21490404.